<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39336888</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Outcomes and Patterns of Evolution of Patients with Hematological Malignancies during the COVID-19 Pandemic: A Nationwide Study (2020-2022).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5400</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13185400</ELocationID><Abstract><AbstractText><b>Background</b>: Early reports suggest that hematological malignancy (HM) is a relevant risk factor for morbidity and mortality in COVID-19. We investigated the characteristics, outcomes, and risk factors for mortality in patients hospitalized with HM and COVID-19. <b>Methods</b>: We conducted a retrospective, nationwide study using data from hospitalized patients that were provided by the Spanish Ministry of Health including all patients admitted to a Spanish hospital from 2020 to 2022 with a COVID-19 diagnosis. A descriptive analysis and correlational analyses were conducted. Logistic regression was used to assess mortality in these patients and to calculate odds ratios (ORs). <b>Results</b>: We collected data on 1.2 million patients with COVID-19, including 34,962 patients with HMs. The incidence of hospitalization for patients with HMs was 5.8%, and the overall mortality rate was higher than for patients without HMs (19.8% versus 12.7%, <i>p</i> = 0.001). Mortality rates were higher for patients with lymphomas, multiple myelomas, and leukemias than for those with myeloproliferative disorders. Having HMs was a risk factor for mortality, with OR = 1.7 (95% CI 1.66-1.75, <i>p</i> = 0.001). By subtype, non-Hodgkin lymphomas were the highest risk factor for mortality (OR = 1.7), followed by leukemias (OR = 1.6), Hodgkin lymphomas (OR = 1.58), and plasma cell dyscrasias (OR = 1.24). <b>Conclusions</b>: This study identifies the different clinical profiles of patients with HMs who are at a high risk for mortality when hospitalized with COVID-19. As members of a vulnerable population, these patients deserve special prophylactic and therapeutic measures to minimize the effects of SARS-CoV-2 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Carretero</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7532-4585</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department, Mostoles University Hospital, Rey Juan Carlos University, 29835 Mostoles, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ordoñez-Garcia</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology Department, Mostoles University Hospital, Rey Juan Carlos University, 29835 Mostoles, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-Prieto</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5229-3832</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Rey Juan Carlos University, 28922 Alcorcón, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-de-Miguel</LastName><ForeName>Angel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1295-7101</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine and Public Health, Rey Juan Carlos University, 28922 Alcorcón, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">hematologic malignancy</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39336888</ArticleId><ArticleId IdType="pmc">PMC11431878</ArticleId><ArticleId IdType="doi">10.3390/jcm13185400</ArticleId><ArticleId IdType="pii">jcm13185400</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5:536–544. doi: 10.1038/s41564-020-0695-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0695-z</ArticleId><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovato A., de Filippis C. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms. Ear Nose Throat J. 2020;99:569–576. doi: 10.1177/0145561320920762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0145561320920762</ArticleId><ArticleId IdType="pubmed">32283980</ArticleId></ArticleIdList></Reference><Reference><Citation>Volz E., Mishra S., Ch M., Barrett J.C., Johnson R., Geidelberg L., Hinsley W.R., Laydon D.J., Dabrera G., O’Toole Á., et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593:266–269. doi: 10.1038/s41586-021-03470-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03470-x</ArticleId><ArticleId IdType="pubmed">33767447</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D., Dejnirattisai W., Supasa P., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Tuekprakhon A., Nutalai R., et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184:2348–2361.e6. doi: 10.1016/j.cell.2021.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.037</ArticleId><ArticleId IdType="pmc">PMC7901269</ArticleId><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  COVID-19 Deaths|WHO COVID-19 Dashboard. 2024.  [(accessed on 8 April 2024)].  Available online:  http://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>Salmanton-García J., Marchesi F., Farina F., Weinbergerová B., Itri F., Dávila-Valls J., Martín-Pérez S., Glenthøj A., Hersby D.S., da Silva M.G., et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553. doi: 10.1016/j.eclinm.2024.102553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2024.102553</ArticleId><ArticleId IdType="pmc">PMC10963230</ArticleId><ArticleId IdType="pubmed">38533127</ArticleId></ArticleIdList></Reference><Reference><Citation>Langerbeins P., Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140:236–252. doi: 10.1182/blood.2021012251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012251</ArticleId><ArticleId IdType="pmc">PMC9098396</ArticleId><ArticleId IdType="pubmed">35544585</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti F., Nicastri E., Di Rocco A., Guarini A., Ibatici A., Luminari S., Mikulska M., Visco C. Management of patients with lymphoma and COVID-19: Narrative review and evidence-based practical recommendations. Hematol. Oncol. 2023;41:3–15. doi: 10.1002/hon.3086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.3086</ArticleId><ArticleId IdType="pmc">PMC9874581</ArticleId><ArticleId IdType="pubmed">36251481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien K.S., Peterson C.B., Young E., Chihara D., Manasanch E.E., Ramdial J.L., Thompson P.A. Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. Blood Adv. 2023;7:5691–5697. doi: 10.1182/bloodadvances.2022008827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022008827</ArticleId><ArticleId IdType="pmc">PMC9896882</ArticleId><ArticleId IdType="pubmed">36696472</ArticleId></ArticleIdList></Reference><Reference><Citation>He W., Chen L., Chen L., Yuan G., Fang Y., Chen W., Wu D., Liang B., Lu X., Ma Y., et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34:1637–1645. doi: 10.1038/s41375-020-0836-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0836-7</ArticleId><ArticleId IdType="pmc">PMC7180672</ArticleId><ArticleId IdType="pubmed">32332856</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carretero R., Vazquez-Gomez O., Gil-Prieto R., Gil-de Miguel A. Hospitalization burden and epidemiology of the COVID-19 pandemic in Spain (2020–2021) BMC Infect. Dis. 2023;23:476. doi: 10.1186/s12879-023-08454-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08454-y</ArticleId><ArticleId IdType="pmc">PMC10353154</ArticleId><ArticleId IdType="pubmed">37464303</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano L., Salmanton-García J., Marchesi F., Busca A., Corradini P., Hoenigl M., Klimko N., Koehler P., Pagliuca A., Passamonti F., et al. COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA) J. Hematol. Oncol. 2021;14:168. doi: 10.1186/s13045-021-01177-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-021-01177-0</ArticleId><ArticleId IdType="pmc">PMC8515781</ArticleId><ArticleId IdType="pubmed">34649563</ArticleId></ArticleIdList></Reference><Reference><Citation>Suárez-García I., Perales-Fraile I., González-García A., Muñoz-Blanco A., Manzano L., Fabregate M., Díez-Manglano J., Aizpuru E.F., Fernández F.A., García A.G., et al. In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain. PLoS ONE. 2021;16:e0255524. doi: 10.1371/journal.pone.0255524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255524</ArticleId><ArticleId IdType="pmc">PMC8330927</ArticleId><ArticleId IdType="pubmed">34343222</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Carretero R., Vazquez-Gomez O., Ordoñez-Garcia M., Garrido-Peño N., Gil-Prieto R., Gil-de Miguel A. Differences in Trends in Admissions and Outcomes among Patients from a Secondary Hospital in Madrid during the COVID-19 Pandemic: A Hospital-Based Epidemiological Analysis (2020–2022) Viruses. 2023;15:1616. doi: 10.3390/v15071616.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15071616</ArticleId><ArticleId IdType="pmc">PMC10384448</ArticleId><ArticleId IdType="pubmed">37515302</ArticleId></ArticleIdList></Reference><Reference><Citation>Instituto de Salud Carlos III. Centro Nacional de Epidemiología  Informe no 128 Situación de COVID-19 en España a 10 de Mayo de 2022.pdf. 2022.  [(accessed on 9 June 2022)].  Available online:  https://repisalud.isciii.es/handle/20.500.12105/19497.</Citation></Reference><Reference><Citation>Sociedad Española de Oncología Médica  Las Cifras del Cáncer en España. 2022.  [(accessed on 29 March 2022)].  Available online:  https://seom.org/prensa/el-cancer-en-cifras.</Citation></Reference><Reference><Citation>Vijenthira A., Gong I.Y., Fox T.A., Booth S., Cook G., Fattizzo B., Martín-Moro F., Razanamahery J., Riches J.C., Zwicker J., et al. Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892. doi: 10.1182/blood.2020008824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008824</ArticleId><ArticleId IdType="pmc">PMC7746126</ArticleId><ArticleId IdType="pubmed">33113551</ArticleId></ArticleIdList></Reference><Reference><Citation>Yigenoglu T.N., Bascı S., Dal M.S., Korkmaz S., Turgut B., Altuntas F. The outcome of COVID-19 in patients with hematological malignancy. J. Med Virol. 2021;93:1099–1104. doi: 10.1002/jmv.26607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26607</ArticleId><ArticleId IdType="pmc">PMC7436524</ArticleId><ArticleId IdType="pubmed">32776581</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-López J., De la Cruz J., Gil-Manso R., Alegre A., Ortiz J., Llamas P., Martínez Y., Hernández-Rivas J.Á., González-Gascón I., Benavente C., et al. COVID-19 severity and survival over time in patients with hematologic malignancies: A population-based registry study. Cancers. 2023;15:1497. doi: 10.3390/cancers15051497.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15051497</ArticleId><ArticleId IdType="pmc">PMC10001264</ArticleId><ArticleId IdType="pubmed">36900296</ArticleId></ArticleIdList></Reference><Reference><Citation>Regalado-Artamendi I., Jimenez-Ubieto A., Hernandez-Rivas J.A., Navarro B., Nuñez L., Alaez C., Córdoba R., Peñalver F.J., Cannata J., Estival P., et al. Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study. Hemasphere. 2021;5:e538. doi: 10.1097/HS9.0000000000000538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HS9.0000000000000538</ArticleId><ArticleId IdType="pmc">PMC7886434</ArticleId><ArticleId IdType="pubmed">33604516</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat M.M., Zińczuk A., Biernat P., Bogucka-Fedorczuk A., Kwiatkowski J., Kalicińska E., Marciniak D., Simon K., Wróbel T. Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit - High mortality rate in infected patients with haematologic malignancies. J. Clin. Virol. 2020;130:104574. doi: 10.1016/j.jcv.2020.104574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104574</ArticleId><ArticleId IdType="pmc">PMC7395815</ArticleId><ArticleId IdType="pubmed">32769026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Rincon J.M., Lopez-Sampalo A., Cobos-Palacios L., Ricci M., Rubio-Rivas M., Díaz-Simón R., Martín-Escalante M.D., Castañeda-Pérez S., Fernández-Madera-Martínez R., Beato-Perez J.L., et al. Nosocomial COVID-19: A nationwide Spanish study. Gerontology. 2023;69:671–683. doi: 10.1159/000527711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000527711</ArticleId><ArticleId IdType="pmc">PMC9893008</ArticleId><ArticleId IdType="pubmed">36682355</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>